Section 1.01 Entering into a Material Definitive Agreement
At December 15, 2021 (the “Closing Date”), uniQure NV (the “Company”) and certain of its affiliates have entered into a Third Amended and Restated Loan and Guarantee Agreement (the “Amendment”) with Hercules Capital, Inc. (“Hercules”) and various banks and other financial institutions or entities from time to time parties thereto (collectively, the “Lender”), which has amended and restated in its entirety the Second Loan and modified and updated warranty, dated
May 6, 2016by and between the Company, Hercules and the Lenders (the “Loan Agreement”).
Pursuant to the Amendment, the Lenders have agreed to refinance the existing term loans (the “2021 Term Loan”) under the Loan Agreement (including a principal amount of $70 million was in progress on the closing date), terminating the remaining availability of the $35 million under the loan agreement, and make available a new $100 million term loan facility (the “Term Loans”). The company fired $100 million on the closing date, $70 million of which was used to refinance the 2021 Term Loan. Advances under the Term Loans bear interest at a rate equal to the greater of (i) the sum of 7.95%, plus the prime rate minus three and one quarter one percent (3.25%), or (ii) 7.95%. The balance of principal and all accrued but unpaid interest on advances under the Term Loans are due on December 1, 2025. Advances for term loans may be prepaid upon at least five (5) business days written notice. The Company may prepay all or part of the principal outstanding (but for an amount not less than $50 million or less if the applicable outstanding amount is less than $50,000,000 at the time of prepayment), together with a prepayment charge of 1.50%, if paid within the first twenty-four (24) months following the Closing Date.
The Company paid a $500,000 service charge at the closing date.
The foregoing description of the Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the Amendment, a copy of which will be filed as an attachment to the Company’s Annual Report on Form 10-K for the year ended December 31, 2021.
Item 2.03 Creation of a Direct Financial Obligation or an Obligation under a
Off-Balance Sheet Arrangement of a Registrant
The foregoing description in Section 1.01 above regarding the Amendment is incorporated into this Section 2.03 by reference. This description is qualified in its entirety by reference to the full text of the amendment, a copy of which will be filed as an attachment to the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021.
Item 8.01 Other Events
At December 16, 2021, the Company has issued a press release announcing a clinical update on the first patients in the Phase I/II clinical trial of the AMT-130 gene therapy for the treatment of Huntington’s disease. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and incorporated herein by reference.
Item 9.01 Financial statements and supporting documents
Exhibit No. Description
99.1 Press Release of uniQure N.V. dated December 16, 2021 announcing a
clinical update on first patients in phase I/II clinical trial of
AMT-130 gene therapy for the treatment of Huntington's disease.
104 Cover page interactive data file (embedded in the Inline XBRL document).
© Edgar Online, source Previews